AAAAAA

   
Results: 1-9 |
Results: 9
Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes - Prospective analysis from PURSUIT
Authors: Tardiff, BE Jennings, LK Harrington, RA Gretler, D Potthoff, RF Vorchheimer, DA Eisenberg, PR Lincoff, AM Labinaz, M Joseph, DM McDougal, MF Kleiman, NS
Citation: Be. Tardiff et al., Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes - Prospective analysis from PURSUIT, CIRCULATION, 104(4), 2001, pp. 399-405
Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention
Authors: Gilchrist, IC O'Shea, JC Kosoglou, T Jennings, LK Lorenz, TJ Kitt, MM Kleiman, NS Talley, D Aguirre, F Davidson, C Runyon, J Tcheng, JE
Citation: Ic. Gilchrist et al., Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention, CIRCULATION, 104(4), 2001, pp. 406-411
Clinical pharmacology of higher dose eptifibatide in percutaneous coronaryintervention (the PRIDE study)
Authors: Tcheng, JE Talley, JD O'Shea, JC Gilchrist, IC Kleiman, NS Grines, CL Davidson, CJ Lincoff, AM Califf, RM Jennings, LK Kitt, MM Lorenz, TJ
Citation: Je. Tcheng et al., Clinical pharmacology of higher dose eptifibatide in percutaneous coronaryintervention (the PRIDE study), AM J CARD, 88(10), 2001, pp. 1097-1102
Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer PFA-100 during percutaneous coronary intervention
Authors: Madan, M Berkowitz, SD Christie, DJ Jennings, LK Smit, AC Sigmon, KN Glazer, S Tcheng, JE
Citation: M. Madan et al., Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer PFA-100 during percutaneous coronary intervention, AM HEART J, 141(2), 2001, pp. 226-233
Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists
Authors: Jennings, LK Haga, JH Slack, SM
Citation: Lk. Jennings et al., Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists, THROMB HAEM, 84(6), 2000, pp. 1095-1102
Active GPIIb-IIIa conformations that link ligand interaction with cytoskeletal reorganization
Authors: Mondoro, TH White, MM Jennings, LK
Citation: Th. Mondoro et al., Active GPIIb-IIIa conformations that link ligand interaction with cytoskeletal reorganization, BLOOD, 96(7), 2000, pp. 2487-2495
First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: Results of theTIMI 15A and 15B trials
Authors: Giugliano, RP McCabe, CH Sequeira, RF Frey, MJ Henry, TD Piana, RN Tamby, JF Jensen, BK Nicolas, SB Jennings, LK Wise, RJ Braunwald, E
Citation: Rp. Giugliano et al., First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: Results of theTIMI 15A and 15B trials, AM HEART J, 140(1), 2000, pp. 81
The tetraspanin CD9 influences the adhesion, spreading, and pericellular fibronectin matrix assembly of Chinese hamster ovary cells on human plasma fibronectin
Authors: Cook, GA Wilkinson, DA Crossno, JT Raghow, R Jennings, LK
Citation: Ga. Cook et al., The tetraspanin CD9 influences the adhesion, spreading, and pericellular fibronectin matrix assembly of Chinese hamster ovary cells on human plasma fibronectin, EXP CELL RE, 251(2), 1999, pp. 356-371
A CD9, alpha(IIb)beta 3, integrin-associated protein, and GPIb/V/IX complex on the surface of human platelets is influenced by alpha(IIb)beta 3 conformational states
Authors: Longhurst, CM White, MM Wilkinson, DA Jennings, LK
Citation: Cm. Longhurst et al., A CD9, alpha(IIb)beta 3, integrin-associated protein, and GPIb/V/IX complex on the surface of human platelets is influenced by alpha(IIb)beta 3 conformational states, EUR J BIOCH, 263(1), 1999, pp. 104-111
Risultati: 1-9 |